Monitoring -lung Cancer Evolution: a Possible Beginning of a "methylation Era" in TKI Resistance Prediction

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 May 8

PMID 37152062

Authors

Federico Pio Fabrizio

Angelo Sparaneo

Lucia Anna Muscarella

Affiliations

Soon will be listed here.

Abstract

The advances in scientific knowledge on biological therapies of the last two decades have impressively oriented the clinical management of non-small-cell lung cancer (NSCLC) patients. The treatment with tyrosine kinase inhibitors (TKIs) in patients harboring Epidermal Growth Factor Receptor ()-activating mutations is dramatically associated with an improvement in disease control. Anyhow, the prognosis for this selected group of patients remains unfavorable, due to the innate and/or acquired resistance to biological therapies. The methylome analysis of many tumors revealed multiple patterns of methylation at single/multiple cytosine-phosphate-guanine (CpG) sites that are linked to the modulation of several cellular pathways involved in cancer onset and progression. In lung cancer patients, ever increasing evidences also suggest that the association between DNA methylation changes at promoter/intergenic regions and the consequent alteration of gene-expression signatures could be related to the acquisition of resistance to biological therapies. Despite this intriguing hypothesis, large confirmatory studies are demanded to consolidate and finalize many preliminary observations made in this field. In this review, we will summarize the available knowledge about the dynamic role of DNA methylation in -mutated NSCLC patients.

Citing Articles

Tumor Methylation Burden (TMeB) in Non-Small Cell Lung Cancer: A New Way of Thinking About Epigenetics.

Fabrizio F, Muscarella L Int J Mol Sci. 2024; 25(23).

PMID: 39684677 PMC: 11641294. DOI: 10.3390/ijms252312966.

Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment.

Ntzifa A, Marras T, Kallergi G, Kotsakis A, Georgoulias V, Lianidou E Front Oncol. 2024; 14:1435537.

PMID: 39497713 PMC: 11532185. DOI: 10.3389/fonc.2024.1435537.

References

Wang F, Meng F, Wong S, Cho W, Yang S, Chan L . Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer. Ther Adv Respir Dis. 2020; 14:1753466620915156. PMC: 7303773. DOI: 10.1177/1753466620915156. View

Guibert N, Pradines A, Favre G, Mazieres J . Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. Eur Respir Rev. 2020; 29(155). PMC: 9488537. DOI: 10.1183/16000617.0052-2019. View

Zhang X, Zhang R, Zheng Y, Shen J, Xiao D, Li J . Expression of gamma-aminobutyric acid receptors on neoplastic growth and prediction of prognosis in non-small cell lung cancer. J Transl Med. 2013; 11:102. PMC: 3644491. DOI: 10.1186/1479-5876-11-102. View

Wang J, Wang B, Chu H, Yao Y . Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Onco Targets Ther. 2016; 9:3711-26. PMC: 4922765. DOI: 10.2147/OTT.S106399. View

Liu D, Sun C, Kim N, Bhan C, Tuason J, Chen Y . Comprehensive Analysis of Family Members Prognostic Value and Immune Infiltration in Gastric Cancer. Life (Basel). 2021; 11(6). PMC: 8228899. DOI: 10.3390/life11060522. View

Nagasaka M, Zhu V, Lim S, Greco M, Wu F, Ou S . Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. J Thorac Oncol. 2020; 16(5):740-763. DOI: 10.1016/j.jtho.2020.11.028. View

Leonetti A, Minari R, Mazzaschi G, Gnetti L, La Monica S, Alfieri R . Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review. Front Oncol. 2021; 11:642190. PMC: 8107466. DOI: 10.3389/fonc.2021.642190. View

Westover D, Zugazagoitia J, Cho B, Lovly C, Paz-Ares L . Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018; 29(suppl_1):i10-i19. PMC: 6454547. DOI: 10.1093/annonc/mdx703. View

Villicana S, Bell J . Genetic impacts on DNA methylation: research findings and future perspectives. Genome Biol. 2021; 22(1):127. PMC: 8086086. DOI: 10.1186/s13059-021-02347-6. View

10.

Reda El Sayed S, Cristante J, Guyon L, Denis J, Chabre O, Cherradi N . MicroRNA Therapeutics in Cancer: Current Advances and Challenges. Cancers (Basel). 2021; 13(11). PMC: 8198729. DOI: 10.3390/cancers13112680. View

11.

Soria J, Lee H, Lee J, Wang L, Issa J, Kemp B . Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 2002; 8(5):1178-84. View

12.

Shirasaki T, Honda M, Yamashita T, Nio K, Shimakami T, Shimizu R . The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication. Sci Rep. 2018; 8(1):13143. PMC: 6120883. DOI: 10.1038/s41598-018-31421-6. View

13.

Feinberg A, Koldobskiy M, Gondor A . Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet. 2016; 17(5):284-99. PMC: 4888057. DOI: 10.1038/nrg.2016.13. View

14.

Wang Z, Zhang L, Xu W, Li J, Liu Y, Zeng X . The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in -Mutant NSCLC. J Inflamm Res. 2022; 15:649-667. PMC: 8818984. DOI: 10.2147/JIR.S341001. View

15.

Hou T, Ma J, Hu C, Zou F, Jiang S, Wang Y . Decitabine reverses gefitinib resistance in PC9 lung adenocarcinoma cells by demethylation of RASSF1A and GADD45β promoter. Int J Clin Exp Pathol. 2020; 12(11):4002-4010. PMC: 6949799. View

16.

Maharati A, Zanguei A, Khalili-Tanha G, Moghbeli M . MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells. Cell Commun Signal. 2022; 20(1):27. PMC: 8905758. DOI: 10.1186/s12964-022-00840-4. View

17.

Nguyen H, Cao N, Nguyen T, Le K, Nguyen D, Nguyen Q . Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations. Sci Rep. 2021; 11(1):16436. PMC: 8361064. DOI: 10.1038/s41598-021-95985-6. View

18.

Angeles A, Janke F, Bauer S, Christopoulos P, Riediger A, Sultmann H . Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer. Cancers (Basel). 2021; 13(22). PMC: 8616179. DOI: 10.3390/cancers13225615. View

19.

Locke W, Guanzon D, Ma C, Liew Y, Duesing K, Fung K . DNA Methylation Cancer Biomarkers: Translation to the Clinic. Front Genet. 2019; 10:1150. PMC: 6870840. DOI: 10.3389/fgene.2019.01150. View

20.

Wu L, Ke L, Zhang Z, Yu J, Meng X . Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors. Front Oncol. 2021; 10:602762. PMC: 7775519. DOI: 10.3389/fonc.2020.602762. View